EUVIMEDEUVIMED entdecken
Crossref

PSMA‐Targeted Nanoparticles with PI3K/mTOR Dual Inhibitor Downregulate P‐Glycoprotein and Inactivate Myeloid‐Derived Suppressor Cells for Enhanced Chemotherapy and Immunotherapy in Prostate Cancer

Lu Yin, Feiya Yang, Wenkuan Wang, Lingpu Zhang, Zheng Cao, Haoyuan Shi, Kehao Pan, Liyuan Wu, Haihua Xiao, Nianzeng Xing iD

Advanced Materials · 2025-07 · 37 (26)

DOI: 10.1002/adma.202415322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 21.04.2025. Verfasst von Lu Yin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and P…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Myeloid-Derived Suppressor Cells, Nanoparticles, Immunotherapy. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Key R&D Program of China, CAMS Innovation Fund for Medical Sciences, Special Research Fund for Central Universities, Peking Union Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired drug resistance and the immunosuppressive tumor microenvironment significantly limit the efficacy of chemotherapy and immunotherapy in advanced prostate cancer. Blocking the PI3K/mTOR signaling pathway has been recently proved as a new strategy to improve sensitivity to chemotherapy and immunotherapy. Herein, glutathione (GSH)‐sensitive nanoparticles (PSMA‐NP/BEZ) are developed that can target prostate‐specific membrane antigen (PSMA), loaded with PI3K/mTOR dual inhibitor prodrug BEZ235. BEZ235 can be released from PSMA‐NP/BEZ in response to elevated GSH levels in prostate cancer tissues, inhibiting the PI3K/AKT/mTOR pathway and impairing downstream cellular functions such as cell proliferation, DNA repair, and protein synthesis. When combined with paclitaxel, PSMA‐NP/BEZ could reduce drug efflux by downregulating P‐glycoprotein expression in cancer cells, thus enhancing the sensitivity to chemotherapy. Furthermore, PSMA‐NP/BEZ could impair the immunosuppressive functions of myeloid‐derived suppressor cells and reshape the “cold” immune microenvironment in prostate cancer, enhancing immunotherapeutic efficacy and including long‐term immune memory against tumor recurrence. PSMA‐NP/BEZ serves a safe and promising strategy to improve the efficacy of chemotherapy and immunotherapy in advanced prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMyeloid-Derived Suppressor CellsNanoparticlesImmunotherapyGlutamate Carboxypeptidase IIMTOR InhibitorsATP Binding Cassette Transporter, Subfamily B, Member 1Phosphoinositide-3 Kinase InhibitorsAntigens, SurfaceAntineoplastic AgentsMaleHumansAnimalsCell Line, TumorTOR Serine-Threonine KinasesPhosphatidylinositol 3-KinasesImidazolesQuinolinesDown-RegulationMiceTumor MicroenvironmentGlutathionePaclitaxel

Stichwörter der Autor:innen

PI3K/mTOR inhibitorP‐glycoproteindrug resistancemyeloid‐derived suppressor cellsnanoparticlesprostate‐specific membrane antigen

Substanzen

TOR Serine-Threonine KinasesPhosphatidylinositol 3-KinasesGlutamate Carboxypeptidase IIdactolisibMTOR InhibitorsATP Binding Cassette Transporter, Subfamily B, Member 1ImidazolesQuinolinesFOLH1 protein, humanPhosphoinositide-3 Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China.
  • State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P.…
  • Beijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry Chinese Academy of Sciences, Beijing, 100190, P. R. China.
  • Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, CA, 90066, USA.
  • Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China.

ORCID-Profile: Nianzeng Xing

Förderung

  • National Key R&D Program of China
  • CAMS Innovation Fund for Medical Sciences
  • Special Research Fund for Central Universities, Peking Union Medical College
  • National Key Research and Development Program of China

Zitieren

APA

Yin, L., Yang, F., Wang, W., Zhang, L., Cao, Z., Shi, H., Pan, K., Wu, L., Xiao, H., & Xing, N. (2025). PSMA‐Targeted Nanoparticles with PI3K/mTOR Dual Inhibitor Downregulate P‐Glycoprotein and Inactivate Myeloid‐Derived Suppressor Cells for Enhanced Chemotherapy and Immunotherapy in Prostate Cancer. Advanced Materials, 37(26). https://doi.org/10.1002/adma.202415322

Vancouver

Yin L, Yang F, Wang W, Zhang L, Cao Z, Shi H, et al. PSMA‐Targeted Nanoparticles with PI3K/mTOR Dual Inhibitor Downregulate P‐Glycoprotein and Inactivate Myeloid‐Derived Suppressor Cells for Enhanced Chemotherapy and Immunotherapy in Prostate Cancer. Advanced Materials. 2025;37(26). doi:10.1002/adma.202415322

BibTeX
@article{Yin2025,
  author = {Yin, Lu and Yang, Feiya and Wang, Wenkuan and Zhang, Lingpu and Cao, Zheng and Shi, Haoyuan and Pan, Kehao and Wu, Liyuan and Xiao, Haihua and Xing, Nianzeng},
  title = {PSMA‐Targeted Nanoparticles with PI3K/mTOR Dual Inhibitor Downregulate P‐Glycoprotein and Inactivate Myeloid‐Derived Suppressor Cells for Enhanced Chemotherapy and Immunotherapy in Prostate Cancer},
  journal = {Advanced Materials},
  year = {2025},
  volume = {37},
  number = {26},
  doi = {10.1002/adma.202415322}
}
Kostenlos starten →